Status epilepticus - Lessons and challenges from animal models

Inna Keselman, Claude G. Wasterlain, Jerome Niquet, James W.Y. Chen

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Status epilepticus (SE) is not simply a prolonged seizure. Both the clinical course and the basic mechanisms are different from a single seizure. SE often fails to respond to sequential administration of antiepileptic drugs (AEDs), originally developed for treatment of chronic seizures. Pharmacoresistance to benzodiazepines and other AEDs, which is observed soon after onset of SE, leads to loss of the effectiveness of these medications and to poor clinical outcomes. Animal models have uncovered SE-induced changes in cellular and network pathophysiology, most of them maladaptive, leading to increased excitability. Whole-cell recordings from hippocampal slices obtained from animals in SE showed alteration in both inhibitory and excitatory postsynaptic physiology. These synaptic changes result at least in part from a decrease in functional synaptic GABAA receptors (through internalization/desensitization) accompanied by a simultaneous increase in the number of membrane NMDA receptors. These findings highlight the role played by receptor trafficking in transition to and maintenance of SE. They explain, at least in part, the development of pharmacoresistance to benzodiazepines and other GABAergic drugs. These SE-associated changes suggest that the current gold standard (benzodiazepine monotherapy) treats only half the problem and that consideration should be given to using a combination of GABAA agonists and NMDA antagonists in the initial treatment.

Original languageEnglish (US)
Title of host publicationCurrent Clinical Neurology
PublisherHumana Press Inc.
Pages3-17
Number of pages15
Edition9783319495552
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Publication series

NameCurrent Clinical Neurology
Number9783319495552
ISSN (Print)1559-0585

Fingerprint

Status Epilepticus
Animal Models
Benzodiazepines
Anticonvulsants
Seizures
GABA-A Receptor Agonists
Neurotransmitter Receptor
Patch-Clamp Techniques
N-Methylaspartate
GABA-A Receptors
N-Methyl-D-Aspartate Receptors
Epilepsy
Maintenance
Membranes
Pharmaceutical Preparations

Keywords

  • Animal models
  • Brain slices
  • Electrical stimulation
  • Gamma-aminobutyric acid
  • Kainic acid
  • N-Methyl-d-aspartic acid or N-methyl-d-aspartate
  • Nerve gas
  • Pharmacoresistance
  • Pilocarpine
  • Status epilepticus

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Keselman, I., Wasterlain, C. G., Niquet, J., & Chen, J. W. Y. (2017). Status epilepticus - Lessons and challenges from animal models. In Current Clinical Neurology (9783319495552 ed., pp. 3-17). (Current Clinical Neurology; No. 9783319495552). Humana Press Inc.. https://doi.org/10.1007/978-3-319-49557-6_1

Status epilepticus - Lessons and challenges from animal models. / Keselman, Inna; Wasterlain, Claude G.; Niquet, Jerome; Chen, James W.Y.

Current Clinical Neurology. 9783319495552. ed. Humana Press Inc., 2017. p. 3-17 (Current Clinical Neurology; No. 9783319495552).

Research output: Chapter in Book/Report/Conference proceedingChapter

Keselman, I, Wasterlain, CG, Niquet, J & Chen, JWY 2017, Status epilepticus - Lessons and challenges from animal models. in Current Clinical Neurology. 9783319495552 edn, Current Clinical Neurology, no. 9783319495552, Humana Press Inc., pp. 3-17. https://doi.org/10.1007/978-3-319-49557-6_1
Keselman I, Wasterlain CG, Niquet J, Chen JWY. Status epilepticus - Lessons and challenges from animal models. In Current Clinical Neurology. 9783319495552 ed. Humana Press Inc. 2017. p. 3-17. (Current Clinical Neurology; 9783319495552). https://doi.org/10.1007/978-3-319-49557-6_1
Keselman, Inna ; Wasterlain, Claude G. ; Niquet, Jerome ; Chen, James W.Y. / Status epilepticus - Lessons and challenges from animal models. Current Clinical Neurology. 9783319495552. ed. Humana Press Inc., 2017. pp. 3-17 (Current Clinical Neurology; 9783319495552).
@inbook{2f5d53efa73e43f193957167117839bd,
title = "Status epilepticus - Lessons and challenges from animal models",
abstract = "Status epilepticus (SE) is not simply a prolonged seizure. Both the clinical course and the basic mechanisms are different from a single seizure. SE often fails to respond to sequential administration of antiepileptic drugs (AEDs), originally developed for treatment of chronic seizures. Pharmacoresistance to benzodiazepines and other AEDs, which is observed soon after onset of SE, leads to loss of the effectiveness of these medications and to poor clinical outcomes. Animal models have uncovered SE-induced changes in cellular and network pathophysiology, most of them maladaptive, leading to increased excitability. Whole-cell recordings from hippocampal slices obtained from animals in SE showed alteration in both inhibitory and excitatory postsynaptic physiology. These synaptic changes result at least in part from a decrease in functional synaptic GABAA receptors (through internalization/desensitization) accompanied by a simultaneous increase in the number of membrane NMDA receptors. These findings highlight the role played by receptor trafficking in transition to and maintenance of SE. They explain, at least in part, the development of pharmacoresistance to benzodiazepines and other GABAergic drugs. These SE-associated changes suggest that the current gold standard (benzodiazepine monotherapy) treats only half the problem and that consideration should be given to using a combination of GABAA agonists and NMDA antagonists in the initial treatment.",
keywords = "Animal models, Brain slices, Electrical stimulation, Gamma-aminobutyric acid, Kainic acid, N-Methyl-d-aspartic acid or N-methyl-d-aspartate, Nerve gas, Pharmacoresistance, Pilocarpine, Status epilepticus",
author = "Inna Keselman and Wasterlain, {Claude G.} and Jerome Niquet and Chen, {James W.Y.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-3-319-49557-6_1",
language = "English (US)",
series = "Current Clinical Neurology",
publisher = "Humana Press Inc.",
number = "9783319495552",
pages = "3--17",
booktitle = "Current Clinical Neurology",
edition = "9783319495552",

}

TY - CHAP

T1 - Status epilepticus - Lessons and challenges from animal models

AU - Keselman, Inna

AU - Wasterlain, Claude G.

AU - Niquet, Jerome

AU - Chen, James W.Y.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Status epilepticus (SE) is not simply a prolonged seizure. Both the clinical course and the basic mechanisms are different from a single seizure. SE often fails to respond to sequential administration of antiepileptic drugs (AEDs), originally developed for treatment of chronic seizures. Pharmacoresistance to benzodiazepines and other AEDs, which is observed soon after onset of SE, leads to loss of the effectiveness of these medications and to poor clinical outcomes. Animal models have uncovered SE-induced changes in cellular and network pathophysiology, most of them maladaptive, leading to increased excitability. Whole-cell recordings from hippocampal slices obtained from animals in SE showed alteration in both inhibitory and excitatory postsynaptic physiology. These synaptic changes result at least in part from a decrease in functional synaptic GABAA receptors (through internalization/desensitization) accompanied by a simultaneous increase in the number of membrane NMDA receptors. These findings highlight the role played by receptor trafficking in transition to and maintenance of SE. They explain, at least in part, the development of pharmacoresistance to benzodiazepines and other GABAergic drugs. These SE-associated changes suggest that the current gold standard (benzodiazepine monotherapy) treats only half the problem and that consideration should be given to using a combination of GABAA agonists and NMDA antagonists in the initial treatment.

AB - Status epilepticus (SE) is not simply a prolonged seizure. Both the clinical course and the basic mechanisms are different from a single seizure. SE often fails to respond to sequential administration of antiepileptic drugs (AEDs), originally developed for treatment of chronic seizures. Pharmacoresistance to benzodiazepines and other AEDs, which is observed soon after onset of SE, leads to loss of the effectiveness of these medications and to poor clinical outcomes. Animal models have uncovered SE-induced changes in cellular and network pathophysiology, most of them maladaptive, leading to increased excitability. Whole-cell recordings from hippocampal slices obtained from animals in SE showed alteration in both inhibitory and excitatory postsynaptic physiology. These synaptic changes result at least in part from a decrease in functional synaptic GABAA receptors (through internalization/desensitization) accompanied by a simultaneous increase in the number of membrane NMDA receptors. These findings highlight the role played by receptor trafficking in transition to and maintenance of SE. They explain, at least in part, the development of pharmacoresistance to benzodiazepines and other GABAergic drugs. These SE-associated changes suggest that the current gold standard (benzodiazepine monotherapy) treats only half the problem and that consideration should be given to using a combination of GABAA agonists and NMDA antagonists in the initial treatment.

KW - Animal models

KW - Brain slices

KW - Electrical stimulation

KW - Gamma-aminobutyric acid

KW - Kainic acid

KW - N-Methyl-d-aspartic acid or N-methyl-d-aspartate

KW - Nerve gas

KW - Pharmacoresistance

KW - Pilocarpine

KW - Status epilepticus

UR - http://www.scopus.com/inward/record.url?scp=85045962905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045962905&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-49557-6_1

DO - 10.1007/978-3-319-49557-6_1

M3 - Chapter

AN - SCOPUS:85045962905

T3 - Current Clinical Neurology

SP - 3

EP - 17

BT - Current Clinical Neurology

PB - Humana Press Inc.

ER -